Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 11:40:11 03/05/2024 am IST 		5-day change 1st Jan Change
0.435 AUD +3.57% Intraday chart for Immutep Limited +12.99% +26.09%
02/05 Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma CI
02/05 Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 84.71 75.58 411.5 247.7 374 499.3 - -
Enterprise Value (EV) 1 75.79 58.31 350.9 169.2 251.4 424.2 437.6 454
P/E ratio -4.39 x -4.61 x -10.9 x -7.65 x -7.05 x -11.1 x -11.7 x 31 x
Yield - - - - - - - -
Capitalization / Revenue 11.3 x 4.58 x - 36.7 x 71.9 x 121 x 28 x 3.73 x
EV / Revenue 10.1 x 3.53 x - 25 x 48.3 x 102 x 24.6 x 3.39 x
EV / EBITDA -4.14 x - -20 x -5.63 x -6.65 x -9.26 x -10.5 x 11.2 x
EV / FCF -4.94 x -5.37 x -19.9 x -5.59 x -7.09 x -9.03 x -6.95 x 4.66 x
FCF Yield -20.2% -18.6% -5.03% -17.9% -14.1% -11.1% -14.4% 21.5%
Price to Book - - - 2.62 x 2.74 x 5 x 8.87 x 4.08 x
Nbr of stocks (in thousands) 3,38,860 4,87,631 7,48,153 8,54,123 11,87,306 11,88,835 - -
Reference price 2 0.2500 0.1550 0.5500 0.2900 0.3150 0.4200 0.4200 0.4200
Announcement Date 20/08/19 25/08/20 30/08/21 31/08/22 29/08/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.489 16.5 - 6.758 5.2 4.143 17.82 133.8
EBITDA 1 -18.32 - -17.59 -30.05 -37.81 -45.83 -41.64 40.57
EBIT 1 -20.2 -12.31 -19.66 -32.12 -39.88 -46.74 -43.45 24.59
Operating Margin -269.66% -74.61% - -475.26% -766.83% -1,128.18% -243.77% 18.38%
Earnings before Tax (EBT) 1 -18.34 -13.47 -29.9 -32.21 -39.9 -44.98 -42.92 36.5
Net income 1 -18.34 -13.47 -29.9 -32.21 -39.9 -44.58 -42.57 10.24
Net margin -244.93% -81.63% - -476.63% -767.22% -1,076.09% -238.84% 7.65%
EPS 2 -0.0570 -0.0336 -0.0503 -0.0379 -0.0447 -0.0379 -0.0359 0.0135
Free Cash Flow 1 -15.33 -10.86 -17.66 -30.25 -35.44 -47 -63 97.5
FCF margin -204.66% -65.81% - -447.65% -681.49% -1,134.53% -353.47% 72.88%
FCF Conversion (EBITDA) - - - - - - - 240.32%
FCF Conversion (Net income) - - - - - - - 952.58%
Dividend per Share 2 - - - - - - - -
Announcement Date 20/08/19 25/08/20 30/08/21 31/08/22 29/08/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - - - - 2.08 3.906 - 2.617 4.11 1.5
EBITDA 1 - - -9.341 -8.245 -14.95 -15.68 - - - -23.55
EBIT 1 -5.373 -6.938 -10.39 -9.262 -16.84 -15.86 -20.61 -19.27 -21.22 -24.87
Operating Margin - - - - -809.62% -405.89% - -736.14% -516.19% -1,657.78%
Earnings before Tax (EBT) 1 -5.95 -7.518 -19.84 -10.06 -16.27 -15.94 -20.62 -19.27 -21.23 -23.2
Net income 1 -5.95 -7.518 -19.84 -10.06 -16.27 -15.94 -20.62 -19.27 -21.23 -23.67
Net margin - - - - -782.21% -408.07% - -736.35% -516.45% -1,577.78%
EPS 2 - - -0.0383 -0.0120 -0.0200 -0.0185 -0.0236 - -0.0179 -0.0190
Dividend per Share - - - - - - - - - -
Announcement Date 20/02/20 25/08/20 23/02/21 30/08/21 24/02/23 31/08/22 24/02/23 29/08/23 27/02/24 -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 8.93 17.3 60.6 78.5 123 75.1 61.7 45.4
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -15.3 -10.9 -17.7 -30.3 -35.4 -47 -63 97.5
ROE (net income / shareholders' equity) - - -56.1% -38.5% -34.6% -48.1% -104% -34.6%
ROA (Net income/ Total Assets) - - -46.5% -35% -32% -44.2% -127% -137%
Assets 1 - - 64.32 92.1 124.8 100.9 33.57 -7.482
Book Value Per Share 2 - - - 0.1100 0.1100 0.0800 0.0500 0.1000
Cash Flow per Share 2 - - -0.0300 -0.0400 -0.0400 -0.0200 -0.1000 -
Capex 1 0.04 0.02 0.02 0.02 0.08 0.05 0.07 0.08
Capex / Sales 0.55% 0.12% - 0.34% 1.59% 1.13% 0.37% 0.06%
Announcement Date 20/08/19 25/08/20 30/08/21 31/08/22 29/08/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Immutep Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.42 AUD
Average target price
0.978 AUD
Spread / Average Target
+132.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IMMUTEP LIMITED Stock Immutep Limited
+26.09% 327M
MODERNA, INC. Stock Moderna, Inc.
+26.28% 48.09B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 40.43B
LONZA GROUP AG Stock Lonza Group AG
+46.79% 40.62B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.8B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.88B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IMM Stock
  4. Financials Immutep Limited